SOPHiA GENETICS (SOPH) partnered with Precision for Medicine to enhance biomarker discovery and precision medicine services, Precision for Medicine said Tuesday.
The company said it will integrate SOPHiA's DDM Platform for biomarker discovery, clinical trial assays, and advanced algorithms to expand its clinical trial capabilities.
The partnership will enable biopharma companies to accelerate clinical trial design, patient stratification, and data analysis through AI-driven algorithms that analyze complex multimodal data, including genomic, radiomic, and clinical data, the company said.
Additionally, the company said the MSK-ACCESS liquid biopsy test powered by SOPHiA DDM, supported by AstraZeneca (AZN), will be available as a service for biopharma clients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。